BioCentury on BioBusiness,
Table: Europe's premier league
Back to the parent article
Monday, May 26, 2014
By and large, the top 10% of private European
fundraisers in 2013 were distinguished by differentiated technology platforms
and therapeutic candidates, most of which attracted U.S. investors. Of the 11
companies in Europe's top decile, six are platform companies and four are
developing potentially first-in-class or best-in-class compounds. Specialty
pharma Norgine B.V. is the outlier, with a portfolio of marketed
products including branded generics. Tranched rounds are consolidated as of the
most recent closing as noted. (A) Total amount drawn down in a tranched $184
million series E round raised in 2011, 2012 and 2013; (B) Includes $22.5
million tranche raised in 2010; (C) Includes $23.4 million tranche raised in
2011; (D) Includes $8 million from the conversion of a 2012 convertible
words displayed of
To read this article, you must be an Archives subscriber. Please choose one of the options below.
All contents Copyright © 1993-2015 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Whether you want an individual subscription or need a global group license, we have the products,
the experience and the customer support that biopharma executives, researchers, investors, service providers,
and industry stakeholders have trusted for nearly two decades.
Let our Subscriber Services team customize the best intelligence package available in the industry to meet your needs.
Free Trial Subscription 4 Weeks of Access
BioCentury's Weekly Business Intelligence Journal
Get a 4-week free trial subscription to BioCentury.
Get 4 Weeks Free
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]